Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma

NCT01613846 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT01613846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01613846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma
Lead sponsor
Technical University of Munich
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2012
Completion date
Not reported
Enrollment
544 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma